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Abstract 
Background: Purinergic receptors are expressed in different tissues including the retina. These receptors are involved 
in processes like cell growth, proliferation, activation and survival. ATP is the major activator of P2 receptors. In dia-
betes, there is a constant ATP production and this rise of ATP leads to a persistent activation of purinergic receptors. 
Antagonists of these receptors are used to evaluate their inhibition effects. Recently, the P2X2 has been reported to 
have a neuroprotective role.
Methods: We carried out a study in groups of diabetic and non-diabetic rats (N = 5) treated with intraperitoneal 
injections of PPADS, at 9 and 24 weeks of diabetes. Control group received only the buffer. Animals were euthanized 
at 34 weeks of diabetes or at a matching age. Rat retinas were analyzed with immunohistochemistry and western blot 
using antibodies against GFAP, P2X2, P2Y2 and VEGF-A.
Results: Diabetic animals treated with PPADS disclosed a much more extended staining of VEGF-A than diabetics 
without treatment. A lower protein expression of VEGF-A was found at the retina of diabetic animals without treat-
ment of purinergic antagonists compared to diabetics with the antagonist treatment. Inhibition of P2X2 receptor by 
PPADS decreases cell death in the diabetic rat retina.
Conclusion: Results might be useful for better understanding the pathophysiology of diabetic retinopathy.
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Background
The P2 receptors are divided in two groups: P2X and 
P2Y receptors. P2X receptors are cation-selective chan-
nels with almost equal permeability to  Na+ and  K+, and 
significant permeability to  Ca2+. They gate extracellular 
cationic response to ATP and are widely expressed in the 
central nervous system and in the body periphery, where 
they play important roles in different processes, includ-
ing muscle contraction, modulation of the cardiovascu-
lar and respiratory systems, and transmitter release [1]. 
P2Y receptors are G-protein coupled receptors that are 
divided into two subfamilies. The first family is composed 
of P2Y receptors 1, 2, 4, 6, and 11 that predominantly 
couple to Gq, thereby activating phospholipase C, which 
results in mobilization of intracellular  Ca2+. The second 
family consists of P2Y receptors 12, 13, and 14, which are 
G-coupled that inhibit adenyl-cyclase and regulate ion 
channels. The P2Y receptors account for broad and var-
ied physiological responses such as platelet aggregation, 
granulocyte differentiation, and regulation of vascular 
tone [2, 3].
P2X and P2Y receptor expression in the rat retina has 
been reported before [4–6]. Recent studies have sug-
gested a role for P2 receptors in retinal disease, including 
retinal detachment [7, 8], proliferative vitreoretinopathy 
[9, 10], diabetic retinopathy [11–14], retinal degeneration 
[15, 16] and oxygen-induced retinopathy [17]. Purinergic 
receptors are involved in chronic inflammation [18] and 
their upregulation has been seen in diabetic complica-
tions [19]. Diabetic retinopathy is known to be, at least 
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in part, an inflammatory disease. However, the role of 
purinergic P2 receptors in the inflammatory mechanism 
of diabetic retinopathy (DR) has been scarcely investi-
gated. Moreover, there are very few studies on P2X2 and 
P2Y2 receptors in the disease.
The P2Y2 receptor is activated by ATP and UTP. Dif-
ferent functional studies have shown that P2Y2 receptors 
are present in endothelial cells and fibroblasts [20–24], 
glial cells [25–27], pancreatic cells [28–30], and pitui-
tary cells [1]. Purinergic signaling seems to be a mediator 
between the retina and the RPE [31]. The P2X2 and P2Y2 
have been reported to play a neuroprotective role, par-
ticularly in neuronal survival [32, 33].
Taking into account that purinergic receptors are 
expressed in the rat retina, their participation in chronic 
inflammation as well as in degenerative, metabolic and 
neuroprotective process we thought it was interesting 
to carry out a study on the role of P2X2 and P2Y2 in the 
diabetic retina. For this purpose, we performed a histo-
logical and immunohistochemical analysis in diabetic 
and non-diabetic rats, using pyridoxalphosphate-6-
azophenyl-2′,4′-disulfonic acid (PPADS), a non-specific 
P2X2 and P2Y2-like antagonist. We have also analyzed 
the neurotrophic and pro-inflammatory molecule VEGF-
A considering its interaction with components of the 
purinergic pathway and its role in the development of 
diabetic retinopathy and in the neuroprotection of the 
ischemic injury [34, 35].
Methods
Animal model
Five-month-old Sprage-Dawley male rats were used in 
this study. Animals were kept at constant 12 h/12 h light 
dark cycle with food and water ad libitum. Diabetes was 
induced by an intraperitoneal (IP) dose of streptozotocin 
(STZ) (45 mg/kg) in 100 µL of a 0.1 M solution of citrate 
buffer of 154  mL of NaCl at 4.5 pH [36]. Twenty-four 
hours later diabetes condition was verified by a meas-
urement of fast blood glucose with a tail snipping using 
a sample of 32  µL in the Reflotron System (Boehringer 
Mannheim, Germany). Only animals with fast glycemia 
levels above 180 mg/dL were included in the study. Dia-
betics with levels above 500 mg/dL or less than 180 mg/
dL were excluded from the study (Fig.  1). In addition, 
samples for plasma glucose measurement were taken on 
the last day of experiments.
Treatment with PPADS
The treatment was based on two IP injections of 12.5 mg/
kg of PPADS in 0.1 mL of vehicle (0.9% sodium chloride), 
or 0.1 mL of vehicle, according to the corresponding ani-
mal group. The first injection was given at 9 weeks of dia-
betes and the second one at 24 weeks of diabetes.
Animal study groups
Diabetic groups
Two diabetic groups were made of five diabetic rats each. 
Group 1 was treated with two IP doses of PPADS, while 
Group 2 received two IP injections of 0.1 mL of vehicle.
Fig. 1 Fast glycemia. The two bar charts show the analyses of fast glycemia in two different periods in the seven groups of animals. a Glycemia 
levels at 9 weeks after vehicle or streptozotocin treatment in control and diabetic animals. Measurement was done 1 day before PPADS first cycle 
treatment. All control groups had normal glycemia levels before purinergic receptors antagonist treatment. b Glycemia levels at 34 weeks after two 
purinergic receptors antagonist treatment cycles performed at 9 and 24 weeks of diabetes. Cont. control; PPADS pyridoxalphosphate-6-azophenyl-
2′,4′-disulfonic acid; DBT diabetic
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Non‑diabetic groups
The two control groups included age-matched non-dia-
betic rats. Each group of rats received an IP injection of 
0.1 mL of vehicle solution at the beginning of the study. 
Then, according to the treatment time of diabetic rats, 
five control rats received IP doses of PPADS and five rats 
were treated with IP injections of 0.1 mL of vehicle solu-
tion (PPADS and vehicle control groups).
Diabetic animals and non-diabetic animals were sacri-
ficed at 34 weeks of diabetes or at a matching age, respec-
tively. Animals were handled according to the ARVO 
Statement for the use of animals in ophthalmic research.
Immunohistochemical analyses
The eye was removed and fixed for 48 h in 4% paraform-
aldehyde (Sigma-Aldrich, St Louis, MO). It was then 
immersed in 4 concentrations of glucose (5% overnight, 
7.5, 10 and 20%) for cryoprotection and interlocked with 
resin. Ten-micron sections were obtained and fixed on 
poly-l-lisine-treated glass slides (Shandon AS325 Retrac-
tion). For immunohistochemistry, the sections were first 
incubated with 1  µg/µL of biotinylated goat anti-mouse 
IgG, then in avidin-biotin peroxidase complex Kit and 
finally in 3,3′-diaminobenzidine (DAB)/nickel solution. 
The P2X2 immunoreactivity was analysed using the P2X2 
antibody (sc-25693 Santa Cruz Biotechnology, CA), P2Y2 
by the P2Y2 antibody (sc-15209 Santa Cruz Biotechnol-
ogy, CA) and VEGF-A immunoreactivity was examined 
with VEGF-A antibody (sc-1836 Santa Cruz Biotechnol-
ogy, CA).
Immunofluorescence analyses
Axial sections were revealed using 1  µg/µL of mouse 
anti-goat secondary antibody with fluorescein. Immu-
nofluorescent analysis was done using the Eclipse Nikon 
Microscope (Tokyo, Japan). The GFAP expression was 
studied using 2 µg/µL of mouse anti-GFAP (BIOGENEX, 
4600 Norris Canyon Road, San Ramon, CA, USA), while 
the P2Y2 was analysed using 2 µg/µL of goat anti-P2Y2 
antibody (sc-15209 Santa Cruz Biotechnology, CA).
Western blot (WB)
Isolated retinas were rinsed in the lysis buffer (5  mM 
Tris-HCl pH 6.8, 2  mM  MgCl2, 2  mM EDTA, 65  mM 
NaCl, 1% Triton X-100) and cocktail protease inhibitor 
(Sigma-Aldrich, St. Louis MO, USA). Protein concen-
tration was determined according to Bradford method 
[18]. Total protein (10 μg per well) was used in an elec-
trophoresis on a 12% SDS-polyacrylamide gel and blotted 
onto nitrocellulose. The blot was incubated with primary 
antibody for 1.5  h at room temperature, washed three 
times with Trizma (buffer pH 7.4 with 0.1% of Tween 20) 
and further incubated in a secondary antibody for 1 h at 
room temperature. The bands were visualized using the 
enhanced chemiluminescence detection system (ECL, 
Amersham, Arlington Heights, IL, USA). The dilution 
for each antibody was 1:1000 P2Y2 (sc-15209 Santa Cruz 
Biotechnology, CA), 1/1000 P2X2 (sc-25693 Santa Cruz 
Biotechnology, CA), 1:700 VEGF (sc-1836 Santa Cruz 
Biotechnology, CA), and 1:700 actin (sc-1615 Santa Cruz 
Biotechnology, CA). The secondary antibody used was 
goat conjugated to a streptoavidin-peroxidase enzyme, 
and dilution was 1:10,000. All antibody dilutions were 
made in Trizma-base 0,01  M pH 7,4 with 1% Bovine 
Serum Albumin (BSA).
Histological examination
Rats were anaesthetized with an IP injection of 350 mg/
kg of chloral hydrate. The eye was removed and fixed in 
4% paraformaldehyde (Sigma-Aldrich, St Louis, MO). 
Animals were sacrificed with an overdose of chloral 
hydrate. The eye was left for fixation in 4% paraformalde-
hyde for 1 day. Afterwards, it was immersed in increasing 
concentration of glucose (5% overnight, 7.5, 10 and 20%) 
and interlocked with resin. Ten-micron cryosections 
were obtained (Shandon AS325 Retraction) and stained 
with Hematoxylin and eosin (H&E) as well as Periodic 
acid-schiff (PAS) and eosin for microscopic examination 
using an Eclipse Nikon E800 Microscope (Tokyo, Japan).
Retinal ganglion cell counting and retinal thickness
H&E stained cryosections were analyzed to count RGCs. 
Briefly, retinas were divided on seven sections including 
three fields in central retina, two fields in medial retina 
and two fields in peripheral retina at 40×. RGCs were 
counted in each field for each cryosection, results are 
showed like whole average for each cryosection for each 
group of animals (N = 5).
For retinal thickness, H&E cryosections were observed 
at 40× and 20 measures were taken, one every 300 µM, 
starting on the beginning of peripheral retina. Each 
measure started on Outer Nuclear Layer (ONL) and end 
at RGCs Layer. Results are showed like an average of 
the measures taken in each cryosection for each group 
(N = 5).
Statistical analysis
Results in this work are expressed as a mean ± standard 
error of the mean, and were analyzed with ANOVA and 
Newman–Keuls multiple comparison post-test.
Results
Fast glycemia
Fast glycemia levels were normal (100  mg/dL or below) 
on the day prior to the intraperitoneal injection of STZ 
or vehicle. At day 2 post-injection fast glycemia levels of 
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95 mg/dL or lower and 200 mg/dL or higher were found 
in non-diabetic and diabetic animals, respectively.
Glucose levels were greater than 200  mg/dL in ani-
mals treated with STZ prior to injection with PPADS, 
whereas the control animals had values close to 100 mg/
dL (Fig.  1a). After treatment with PPADS surprisingly, 
the glucose levels of the treated diabetics decreased rela-
tive to the untreated diabetics and the glucose levels in 
the treated controls increased compared to the untreated 
controls (Fig. 1b).
P2Y2 immunoreactivity
Diabetic animals and controls without treatment
P2Y2 immunoreactivity was seen in the ganglion cell layer 
of diabetic and control animals. Diabetic group staining 
had a larger extension and was also observed at the pho-
toreceptor inner segment (Fig. 2A1). As expected, GFAP 
staining was greater in the diabetic groups than control 
(Fig. 2A2, B2). Merge of P2Y2 and GFAP in diabetics and 
controls had similar patterns (Fig. 2A3, B3). In summary, 
the fiber layer, glial cells and the photoreceptor layer P2Y2 
expression was seen in diabetic rats, while in controls the 
P2Y2 expression was slightly observed in the fiber layer. 
Same results were observed for immunofluorescence and 
immunohistochemistry (not shown).
Immunohistochemical analysis of diabetic animals 
and controls treated with PPADS
The immunohistochemical pattern of P2Y2 was quite 
similar in retinas of diabetic animals either treated or not 
treated with PPADS (Fig. 3c, d). The pattern observed in 
diabetics was different from that found in control without 
treatment (Fig.  3a, c). Also, both diabetic groups there 
were a positive immunoreactivity of the photoreceptor 
inner segment, and this was also seen among control ani-
mals treated with a purinergic antagonist (Fig. 3b–d).
P2X2 immunoreactivity
Diabetic animals and controls without treatment
P2X2 immunoreactivity was observed in the ganglion 
cell layer of diabetic and control animals. However, stain-
ing was larger in the control group and it was seen in the 
ganglion cell layer, inner plexiform, outer nuclear and 
photoreceptor layers (Fig. 4a).
Immunohistochemical analysis of diabetic animals 
and controls treated with PPADS
The immunohistochemical pattern of P2X2 was similar 
in retinas of diabetic animals treated or not treated with 
PPADS (Fig. 4b, d). In both groups there was a positive 
immunoreactivity in the ganglion cell and inner nuclear 
Fig. 2 Retinal cross section. Immunofluorescent analyses of diabetic and control animals without purinergic receptors antagonist treatment. A 
Diabetic group (34 weeks after STZ IP injection). B Control group. P2Y2r immunoreactivity was seen in the fiber layer of diabetic and control animals 
(arrow-A1 and B1). In the diabetic group staining had a larger extension. Positive immunoreactivity of GFAP was observed in glial cells of diabetics 
and controls (arrow A2 and B2). In diabetic animals immunoreactivity was much more extended and some GFAP positive cells showed a morphol-
ogy similar to that seen in Müller Cells (arrow head-A2). Co-expression of P2Y2 and GFAP in diabetics and controls had different patterns. In diabetic 
rats co-expression of P2Y2 and GFAP was seen in the fiber layer and in glial cells extending to the photoreceptor layer (A3), while in controls the 
co-expression was slightly observed in the fiber layer (B3)
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layers. Although the immunoreactivity of P2X2 was 
reduced in treated groups respect to control group, the 
difference was more pronounced than that found com-
pared to the diabetic group (Fig. 4a–d).
VEGF‑A immunoreactivity
The pattern was found to be different among control and 
diabetic groups (Fig.  5a, c, d). The extension of immu-
noreactivity was larger in diabetics than in controls. 
VEGF-A immunoreactivity was seen in small vessels, 
fiber layer, INL, and in RPE of all diabetics. However, 
diabetic animals treated with, PPADS disclosed a much 
more extended staining than diabetics without treat-
ment (Fig.  5c, d). In control animals without treatment 
the immunostaining of VEGF-A was observed in vessels, 
INL and the photoreceptor outer segment (Fig. 5a). The 
pattern observed in control animals treated with PPADS 
consisted of positive immunoreactivity of VEGF-A in the 
GCL, INL and PIS (Fig. 5b, d).
P2X2, P2Y2 and VEGF protein expressions
Western blot analyses revealed a significantly lower 
expression of P2X2 in diabetics without treatment than 
control norm glycemic group. Diabetics treated with 
Fig. 3 Retinal cross-sections. P2Y2 immunohistochemistry in diabetic and control animals treated with purinergic receptors antagonist (PPADS). a 
and b represent control groups. c and d represent diabetic groups. b and d groups were treated with intraperitoneal injection of group with PPADS. 
P2Y2r immunostaining was seen in the photoreceptor inner segment in all diabetics and in controls treated with purinergic receptors antagonist. 
GCL ganglion cells layer; INL Inner nuclear layer; PIS photoreceptor inner segment; DBT diabetic; PPADS animals treated with pyridoxalphosphate-6-
azophenyl-2′,4′-disulfonic acid
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the PPADS had higher expression of P2X2 compared to 
diabetic rats without treatment (Fig. 6a, c). Non- signifi-
cant differences were found for P2Y2 protein expression 
between experimental groups (Fig. 6b, d).
We identified two western blot banding patterns for 
VEGF, one at 42 kDa and the other at 40 kDa. The protein 
expression of VEGF-A at 42  kDa was lower in diabetic 
and non-diabetic animals without treatment compared 
to non-diabetics treated with PPADS (Fig. 7a, c). Diabetic 
animals with PPADS treatment showed a similar expres-
sion of VEGF-A than non-diabetic controls without 
treatment. The expression of VEGF at 40 kDa, probably 
corresponding to the 165b dimmer, have a similar expres-
sion pattern than VEGF at 42 kDa (Fig. 7b, c). This is con-
sistent with immunohistochemistry results where VEGF 
showed higher levels of protein expression in PPADS 
treated non-diabetic group (Fig. 5a).
Retinal ganglion cell counting and retinal thickness
The number of RGCs in non-treated diabetic animals 
were lower respect to non-diabetic animals. Diabetic ani-
mals treated with PPADS recovered normal levels of den-
sity of RGCs. The same pattern was reflected with retinal 
thickness (Fig. 8).
Fig. 4 Retinal cross-sections. P2X2 immunohistochemistry in diabetic and control animals treated with purinergic receptors antagonist (PPADS). 
a and b Represent control groups. c and d Represent diabetic groups. b and d Groups were treated with intraperitoneal injection of PPADS. P2X2r 
immunostaining was seen in the photoreceptor inner segment and outer nuclear layer of controls without treatment. In the remaining animal 
groups immunoreactivity was found in the inner nuclear layer. GCL ganglion cells layer; INL Inner nuclear layer; PIS photoreceptor inner segment; 
DBT diabetic; PPADS animals treated with pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid
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Discussion
We carried out a research study to evaluate the role of 
P2Y2 and P2X2 in the retina of a rat model of diabetes. 
The study included diabetic and non-diabetic animals 
divided into subgroups either treated with an intra-
peritoneal injection of vehicle or a purinergic receptor 
antagonist. We found a down-regulation of P2X2 in the 
retina of treated and untreated diabetic animals. How-
ever, with PPADS treatment we observed a higher pro-
tein expression than in non-treated animals, suggesting 
a slightly recovery. It is known that purinergic receptors 
may regulate cell growth in an ATP-dependent manner. 
In this study, we demonstrated that the use of a puriner-
gic antagonist in diabetic animals induced changes in the 
protein expression of VEGF-A. VEGF-A was downregu-
lated in diabetic animals, although, in treated animals 
had the same levels of expression than non-treated con-
trol group. Our results suggest a relationship between 
this neurotrophic and pro-inflammatory agent and the 
purinergic pathway but further experiments are required.
Purinergic signaling seems to be an intermediary in the 
communication between the retina and the RPE [37]. In 
this study, P2Y2 expression at the photoreceptor outer 
segment was observed in all groups of diabetic animals 
Fig. 5 Immunohistochemical analyses of VEGF-A. Immunostaining of VEGF-A was found in two different patterns. b Controls with PPADS treat-
ments showed a positive immunoreactivity in GCL, INL and PIS. a Controls without treatment and c, d diabetic animals showed staining in struc-
tures which may be small vessels (arrows). GCL ganglion cells layer; INL Inner nuclear layer; PIS photoreceptor inner segment; DBT diabetic; PPADS 
animals treated with pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid
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and in the group of non-diabetic animals treated with 
the purinergic antagonist. This finding was not seen in 
non-diabetic animals. As we already know, PPADS has 
a selective effect on P2 receptors, so these results sug-
gest that PPADS have an effect on the P2Y2 expression 
at photoreceptors level. Furthermore, diabetic animals 
have a higher glucose metabolism and an increase in ATP 
production. Besides, ATP may also activate P2 receptors 
of neighboring retinal neurons, such as photoreceptors, 
amacrine cells, and ganglion cells [5, 6, 38]; and we think 
that these changes lead to an augmented purinergic sign-
aling as we have seen in the present study. On the other 
hand, non-diabetic animals (not treated with purinergic 
antagonist) showed lower P2Y2 expression, a fact that 
supports our hypothesis.
The neuroprotective role of P2Y2 and P2X2 has been 
suggested by other researchers [32, 39–42]. Up-regula-
tion of P2Y2 and agonists enhanced this effect in astro-
cytes [43] and a selective antagonist (AR-C118925) could 
inhibit glial activation [44]. In this study, diabetic animals 
treated with PPADS showed a higher protein expression 
of VEGF-A, known to have a neurotrophic effect [34, 35]. 
These findings support the idea of the neuroprotective 
role of P2X2. This situation was also reflected in RGC 
count and retinal thickness in our study.
Pancreatic cells contain stores of ATP as well as 
purinergic receptors [19, 45]. It is well established that 
ATP and ADP induce insulin secretion in presence of glu-
cose, The disturbance of the purinergic pathway caused 
by PPADS might result in changes of insulin and gluca-
gon secretion [45]. The P2X receptor might elicit insulin 
secretion even in low glucose concentration. We think 
that this would explain the unexpected elevated levels of 
fast glycemia observed in non-diabetic animals after two 
treatment cycles of purinergic antagonists. Moreover, we 
think this is an interesting finding that warrants further 
investigation.
The P2Y2 nucleotide receptor seems to inhibit trauma-
induced death of astrocytic cells [46]. This protective 
effect may be achieved through agonists as ATP. Besides, 
a previous study reported a new pathway for neuronal 
survival through the activation of P2Y2 receptor. It is fea-
sible the existence of interacting systems –extracellular 
nucleotides/P2Y2 receptors and neurotrophin/TrkA—to 
sustain the survival of neurons [47]. It is well established 
that diabetes increases cell death of retinal ganglion cells 
Fig. 6 Western blot analyses of P2X2 and P2Y2. a P2X2 densitometry quantification, lower expression was seen in the diabetic and treated 
groups. b P2Y2 densitometry quantification, non-significant differences were found between groups. c P2X2 immunoblot. d P2Y2 immunoblot. 
Diabetic animals treated with PPADS showed higher P2X2 expression levels compared with non-treated diabetic group. Cont. control; PPADS 
pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid; DBT diabetic (*p<0.05; **p<0.01; ***p<0.001)
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by apoptosis [48]. This has probably occurred in the cur-
rent study, where we observed an increased RGC loss and 
a reduced retinal thickness in the diabetic group respect 
to controls and treated diabetic animals.
In non-diabetic treated animals, we found a higher pro-
tein expression of VEGF-A at 42 KDa compared to non-
diabetics without treatment and diabetics with treatment. 
Another study has proposed that VEGF receptor can be 
activated in the absence of VEGF. P2YR-VEGFR2 could 
interact resulting in a signal transduction that is a critical 
determinant of vascular homeostasis and tumor-mediated 
angiogenesis [49]. Besides, it should be noted that VEGF-
A affects the development of new vessels (angiogenesis) 
[50] as well as the vascular maintenance (endothelial 
cells survival and vascular permeability) and the neuro-
trophism in a physiological condition [34, 35, 51].
In the present study, non-diabetic animals treated 
with purinergic antagonists showed two bands of VEGF-
A expression, one at 42 KD and the other at 40 KDa, 
forming a 2-band pattern. It is known that VEGF-A has 
isoforms depending of the splicing [52]. Most VEGF-A 
producing cells appear to preferentially express VEGF-
A121, VEGFA165 and VEGF-A189, and murine coun-
terparts are VEGF-A 120, 164 and 188, respectively. 
VEGF-A 165 is primarily isoform [53]. Its molecular 
weight commonly ranges from 38.2 to 45 [54]. In our 
study PPADS might have hindered ATP binding to P2X2 
causing an increase in free ATP and facilitating the 
binding of ATP to VEGF-A. Binding of ATP to vascular 
endothelial growth factor isoform VEGF-A165 is well-
known [53]. Besides, an identical isoform can have dis-
tinct activities at different anatomical sites, suggesting 
that the microenvironment of different tissues can dic-
tate VEGF-A function [55]. We believe that the difference 
in VEGF-A expression and the 2-band pattern found is 
due to an altered imbalance of signaling in the purinergic 
pathway. Anyhow, new studies need to be undertaken to 
learn the meaning of these facts.
Fig. 7 Western blot analyses of VEGF-A. a 42 KDa band. The expression was lower in diabetic group compared to control group or PPADS groups. 
b 40 KDa band. The expression profile was similar than 42 kDa band. c Inmunoblot. Cont. control; PPADS pyridoxalphosphate-6-azophenyl-2′,4′-
disulfonic acid; DBT diabetic (*p<0.05,**p<0.01, ***p<0.01)
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Conclusions
In our experimental study, we have observed a decrease 
of P2X2 expression in the retina of diabetic rats. In these 
animals, the use of PPADS, a non-specific antagonist for 
purinergic receptors, upregulates the protein expression 
of molecules involved in cell survival and inflammation. 
We hope our study has shed light to mechanisms of dia-
betic retinopathy associated with the  purinergic path-
way. More extensive studies are required to identify the 
exact role of purinergic signaling in diabetic retinopathy 
development.
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